Key Takeaways
- Strong quarter, margin resilience: Revenue grew ~23% YoY with EBITDA margin expanding 121 bps to 24.8%, as the company passed on costs and gained operating leverage against an industry trend of margin pressure.
- Glyphosate notification is a disruption, not a ban: Government restricted usage to pest control operators only; management sees a 30-60 day temporary setback and plans to build PCO infrastructure within 3-6 months to protect sales, calling the safety rationale "ill-founded."
- Export engine firing on all cylinders: Exports surged ~53% in H1, led by a 451% jump in Glyphosate exports to Africa and 49% growth in Latin America, with new Brazil registrations set to add a substantial boost from FY24.
- Domestic volume hit absorbed by pricing: Glyphosate domestic volumes fell 40% in H1 due to poor monsoon and trade caution, but revenue stayed nearly flat because of price increases, while other insecticides and herbicides grew in different pockets.
- What to watch next quarter: Speed of PCO infrastructure build-out for Glyphosate, channel inventory depletion in October-November impacting Rabi offtake, and whether the 30-60 day disruption timeline holds.
Glyphosate: Notification Impact & Response
- Notification specifics: On 25th October 2022, the Government of India restricted Glyphosate usage to spraying only by certified pest control operators; the product itself is not banned and buying/selling through trade and dealer networks is expected to continue uninterrupted.
- Management stance on safety logic: The company views the health-and-safety rationale as "ill-founded," noting zero incidents of health hazards from Glyphosate in 40-50 years of use in India, and points to Sri Lanka's economic collapse after its ban as a cautionary tale.
- Immediate disruption timeline: Management expects a temporary setback of 30-60 days while the industry collectively works out a way forward; raw material procurement decisions are paused for 15-30 days until clarity emerges.
- PCO infrastructure plan: The company intends to set up its own pest control operator infrastructure within 3-6 months, potentially using its field staff network and offering sprayers and drones as value-added services to farmers.
- No market shrinkage expected: Management is emphatic that Glyphosate demand will not shrink because farmers need the product for its unmatched economics and efficacy, and there is no replacement molecule available in the market.
- Industry-wide concern: The entire industry is united on this notification out of fear that if usage restrictions can be imposed on Glyphosate, they could extend to other products, which would be "even more cumbersome" for the sector.
Chetan Shah: "Farmers need this product because it is so economical for them and so important to them that they are not going to give up on this product and there is no replacement of this product, Glyphosate, by any other product that is likely to be available in the market. The way Glyphosate can work no other product can work."
Export Performance & Expansion
- H1 export surge: Exports grew ~53% YoY in H1 FY23, lifting the export share of total revenue from ~15% to ~19%, driven by increased shipments to Europe, North America, South East Asia, and affiliate companies in Latin America.
- Glyphosate export explosion: Glyphosate exports jumped 451% YoY in H1, fueled by the registration of the Mera 71 brand in Sudan and the availability of additional capacity because domestic volumes were down.
- Africa focus: The African market grew over 50% in H1, with main export destinations including Sudan, Ethiopia, and Nigeria where the company sells its own branded formulations, not technical material.
- Latin America momentum: Exports to Latin America grew 49% in H1; management sees no immediate impact from reported regional slowdowns, with second-half orders unaffected and a new combination product launch by the Brazil team this year likely sourcing actives from India.
- Brazil registrations: Sumitomo Chemical India received two new formulated product registrations in Brazil for the off-patent segment, with the company endorsed as the supplier; formulation facility readiness is targeted for Q4 FY23 and commercial supplies for Q1 FY24, expected to give a substantial boost.
- Export margin profile: Management does not believe increasing export salience will materially impact margins; even at a hypothetical 70/30 export-domestic split, the margin profile would not significantly change, and Glyphosate export margins are only a few percentage points below domestic.
Domestic Business & Volume Dynamics
- Domestic growth despite headwinds: Overall domestic sales grew in Q2 despite a 40% YoY volume decline in Glyphosate during H1, because price increases lifted revenue across the portfolio and many insecticides and herbicides grew volumes in other pockets, not as Glyphosate replacements.
- Glyphosate volume decline drivers: The primary cause was climatic: a total lack of pre-monsoon showers delayed demand until late June, followed by continuous rain absence in June-July and then very high rains in August-September. A secondary factor was trade caution in taking inventory positions after prices had risen tremendously versus the prior year.
- Revenue impact contained: While Glyphosate volumes dropped 40% in H1, revenue from the molecule remained almost flat because of price increases, so the amount-wise negative impact was minimal.
- Channel inventory overhang: Some inventory is sitting in the market which will impact sales for the first two months of the Rabi season (October and November); once depleted, fresh supplies will begin at new price levels.
- New product acceptance: Eight new products launched in H1 across insecticides, PGRs, metal phosphate, and fungicide categories, with newly launched 9(3) registration products recording sales in Q2 and accepted well by channel and end users.
Chetan Shah: "while the farmer was not disturbed to use Glyphosate even at a higher price, it was mainly the trade who were scared to take a position on Glyphosate."
Margin Performance & Pricing Philosophy
- Margin expansion against industry trend: EBITDA margin expanded 121 bps YoY to 24.8% in Q2, while H1 margin improved slightly to 22.1% from ~21.5%, achieved despite an industry environment where falling raw material prices from July 2022 onward were expected to pressure gross margins due to high-cost carryover inventories.
- Cost pass-through capability: The company freely passed on rising input costs, aided by operating leverage, better product mix, cost optimization, and synergies; management attributes this to constant two-way communication with channel partners and joint efforts.
- Gross margin stability: H1 gross margin contracted only modestly from 32.8% to 31.8% of sales, more or less in line with the previous year.
- Pricing discipline: If raw material prices decline, the company is willing to drop prices rather than take undue advantage, aiming to maintain profitability, margins, and volumes even at higher trade prices.
- Volume lever on margin protection: In a price-decline scenario, the strategy is to increase volumes to maintain absolute margins; management states explicitly that "you cannot have a drop in the overall topline and you cannot have a drop in overall bottom line."
Chetan Shah: "We were able to freely pass on the rising cost and hence we could improve our margins against the overall industry trend. This gives us immense confidence in strength of our brands, demand generation activities, and strong trusted relationship with our channel partners."
Capex, Capacity & New Initiatives
- Bhavnagar project live: One Make in India project at Bhavnagar for a global proprietary product began commercial production recently; revenues expected in H2 FY23 with full revenues in the next year.
- Tarapur expansion timeline: A second Make in India project at Tarapur, manufacturing multiple products for the parent company, is expected to begin commercial production in Q1 FY24; the site also received approvals for Pyriproxyfen, Diafenthiuron, and four proprietary household products of Sumitomo Japan for worldwide export.
- Dahej land parcel: A land parcel at Dahej has been acquired for new facilities; products are on the drawing board, with major investment expected in FY26; the pipeline will focus on off-patent molecules developed by in-house R&D for both domestic and export markets.
- Bhavnagar land for Tebuconazole: Additional land at Bhavnagar is earmarked for Tebuconazole capacity expansion if global demand rises due to new combination product launches with proprietary molecules.
- Capex return discipline: Management's thumb rule is ₹2 of revenue for every ₹1 invested; "if I do not get Rs.2 revenue for Re.1 investment, I would rather not invest." A personal estimate of ₹250-300 crores in additional capex was floated for new site and product development, over and above normal maintenance.
- Bio-rational pipeline: Three bio-rational products are lined up for registration in India under the Fertilizers Act, with bio-efficacy work and field trials completed showing "fantastic results"; registration is expected to be quicker than under the Insecticides Act.
Chetan Shah: "if I do not get Rs.2 revenue for Re.1 investment, I would rather not invest."
Segment Strategy & Growth Levers
- Herbicides, PGRs, and bio-rationals: These three segments are where management expects the most growth, stability, and profit; new product launches in PGRs are planned to increase contribution and lessen the impact of seasonality.
- Market share from unorganized players: The company anticipates taking share from unorganized players due to its well-established supply chain, recognizable brand names, and reach.
- R&D engine: The in-house R&D team in India continuously develops processes for off-patent products and pre-mixture combination products for the Indian market and global export markets including Latin America, Africa, and Asia Pacific.
- Africa doubling plan: Management plans to double sales in many African countries through new product registrations.
- HTBt cotton catalyst: GEAC has recommended mustard for environmental release, and HTBt cotton is expected to be recommended in the near future, possibly at the next meeting; if approved, adoption to 70% of cotton area may take 2-3 years, potentially expanding Glyphosate's theoretical peak market to ~1.2 crore liters from the current ~0.3 crore liters.
- CIBRC regulatory tailwind: The government recommended that any formulation import must be accompanied by technical registration, with no field trial data required for technical registration, only toxicology, chemistry, packaging, and shelf-life data.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Glyphosate PCO infrastructure | Build own pest control operator network to protect sales | 3-6 months |
| Glyphosate disruption | Temporary setback; back to normal after clarity exercise | 30-60 days |
| Tarapur commercial production | Multiple products for parent company begin production | Q1 FY24 |
| Brazil formulation facility | Facility ready for two newly registered products | Q4 FY23 |
| Brazil commercial supplies | First supplies of two new products to Brazil | Q1 FY24 |
| Bhavnagar proprietary product | Full revenues from recently commenced production | Next year (FY24) |
| Dahej major investment | Major capex chunk for new facilities | FY26 |
| Capex return threshold | ₹2 revenue for every ₹1 invested | Ongoing discipline |
| Bio-rational product registrations | Three products registered under Fertilizers Act | Quicker timeline expected |
| HTBt cotton adoption (if approved) | Adoption to 70% of cotton area | 2-3 years from approval |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹1,122 cr, up ~23% YoY from ₹910 cr |
| EBITDA | ₹278 cr, up 30% YoY from ₹215 cr |
| EBITDA margin | 24.8%, up 121 bps YoY from 23.6% |
| PAT | ₹202 cr, up 31% YoY from ₹154 cr |
| PAT margin | 18%, up 102 bps YoY from 16.9% |
| H1 FY23 revenue | ₹2,107 cr, up ~25% YoY from ₹1,692 cr |
| H1 FY23 EBITDA margin | 22.1%, up from ~21.5% in H1 FY22 |
| H1 FY23 PAT | ₹340 cr, up 31% YoY from ₹260 cr |
| H1 FY23 export growth | ~53% YoY |
| H1 FY23 export share of revenue | ~19%, up from ~15% in H1 FY22 |
| H1 FY23 revenue mix | Insecticides ~41%, Herbicides ~27%, PGR ~10%, Fungicides ~9% |
| Cash and cash equivalents | ₹800 cr as on Sep 30, 2022 |
| Net working capital cycle | 94 days in H1 FY23, up from 72 days in H1 FY22 |
| H1 FY23 domestic Glyphosate volume | Down 40% YoY |
| H1 FY23 Glyphosate export growth | Up 451% YoY |
| Glyphosate domestic market share | 30–40%, depending on price and volumes |
| H1 FY23 new product launches | 8 products: 3 insecticides, 3 PGRs, 1 metal phosphate, 1 fungicide |
| Capex for two Make in India projects | ~₹120 cr |
| H1 FY23 farmer outreach | ~0.44 cr farmers, 31,000 channel partners |
| H1 FY23 digital engagements | ~1.7 cr |
| H1 FY23 gross margin | ~31.8% of sales, vs 32.8% in H1 FY22 |
| H1 FY23 collections | ₹2,131 cr, vs ₹1,875 cr in H1 FY22 |
| Glyphosate gross margin (current year) | 27.5% |
| H1 FY23 Latin America export growth | Up 49% YoY |
| H1 FY23 Africa export growth | Up ~50%+ YoY |
| Glyphosate market size (India, ex-company) | ₹1,100–1,200 cr |
| Five new contract manufacturing products revenue potential | ₹200–250 cr |
| Additional Capex for new sites and products | ~₹250–300 cr over a period (per an analyst's math, management's personal guess) |